By Tony Fong

NEW YORK (GenomeWeb News) – A rapidly changing regulatory environment, slow adoption by clinicians, and the soft economy continue to be barriers to venture capital investments into the molecular diagnostics space, according to some VC investors and officials at MDx firms, with one venture capitalist calling the current environment one of the worst he's seen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.